OnDemand

Blue Fin Group completed a quantitative survey and qualitative in-depth interviews focusing on the evolution of payer management for oncology therapies. The research was conducted with payers overseeing approximately 238 million commercial, Medicare, and Medicaid lives.

Topics discussed within the interviews expand beyond the scope of insights characterized here and consist of:

• Identification of top cancer types by drug spend/budget and by management focus
• Payer approach to oncology management – how products are grouped or not grouped – for purposes of management and P&T review
• Objectives of oncology management and how it is assessed and measured
• Identification of obstacles to managing oncology
• Role of biosimilars in oncology management – today and in the future 
• Current approach to managing NSCLC targeted and immunotherapies • Role of diagnostics in oncology management

Kerri Fortier
Principal Consultant
Blue Fin Group, an IntegriChain Company

Jonny Clark
Consultant
Blue Fin Group, an IntegriChain Company